Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Poland / NCT07857590
Starting soon Not applicable

APPETE INTAKE: A Study on the Effects of Adding an Appetite Engine to a Nutritional Drink

NCT07857590 · tracked via the Priya Life Science Poland tracker
Sponsor
Nutricia Research
Phase
Not applicable
Started
2026-09-15
Last updated
2026-10-05

Condition(s) studied

Appetite Regulation

Investigational drug(s) / intervention(s)

Test nutritional drinkControl nutritional drink

Test nutritional drink: Nutritional drink consumed twice daily

Control nutritional drink: Oral nutritional drink consumed twice daily

Study summary

The aim of this study is to investigate the effect of adding an appetite engine to a high-protein oral nutritional supplement (ONS) on acute dietary intake in older adults.

Eligibility

Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: Adults aged 65 years or older Older adults in need of additional nutritional support, such as those currently using oral nutritional supplements or identified as malnourished or at risk of malnutrition Able to consume oral nutritional drinks as part of daily nutrition Able and willing to provide written informed consent Exclusion Criteria: Medical conditions that significantly affect food intake, digestion, or gastrointestinal function Conditions or treatments known to markedly influence appetite or nutritional intake Known allergies or intolerances to components of the nutritional drinks Use of tube feeding or parenteral nutrition Participation in another interventional study during the study period Any condition that, in the investigator's opinion, could interfere with study participation or compliance

Primary outcome measure(s)

  • Acute dietary intake — Assessed on Day 1 of each intervention period.
    Amount of energy consumed during a single meal after intake of a nutritional drink.

Trial sites (1)

FacilityCityRegionStatus
Novamedpharm Krakow Poland

More Nutricia Research trials in Poland

A Growth Artificial Intelligence Algorithm for leNgth and Weight Study Active, not recruiting
A Randomised, Controlled, Double-blinded, Multi-country, Multi-centre Trial to Study Growth and Health Outcomes of a New Infant- and follow-on Formula for Healthy Term Infants. Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07857590 on ClinicalTrials.gov ↗ ← All trials in Poland